{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05390515",
            "orgStudyIdInfo": {
                "id": "22-36503"
            },
            "organization": {
                "fullName": "University of California, San Francisco",
                "class": "OTHER"
            },
            "briefTitle": "Psoriatic Immune Response to Tildrakizumab",
            "officialTitle": "Psoriatic Immune Response to Tildrakizumab",
            "therapeuticArea": [
                "Dermatology"
            ],
            "study": "psoriatic-immune-response-to-tildrakizumab"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-09-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-09-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-05-20",
            "studyFirstSubmitQcDate": "2022-05-20",
            "studyFirstPostDateStruct": {
                "date": "2022-05-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-25",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of California, San Francisco",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Sun Pharmaceutical Industries Limited",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.",
            "detailedDescription": "This is a one-arm, open-label study to examine the effect of Tildrakizumab on cutaneous and blood immune cells of psoriatic patients. Ten subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for tildrakizumab-corrected signatures."
        },
        "conditionsModule": {
            "conditions": [
                "Psoriasis Vulgaris"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Tildrakizumab treatment",
                    "type": "EXPERIMENTAL",
                    "description": "Biological/vaccine: tildrakizumab",
                    "interventionNames": [
                        "Drug: Tildrakizumab Prefilled Syringe"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tildrakizumab Prefilled Syringe",
                    "description": "IL-23 inhibitor",
                    "armGroupLabels": [
                        "Tildrakizumab treatment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Psoriasis Area and Severity Index (PASI) Score at baseline and 3 months of treatment",
                    "description": "Change in severity and extent of psoriasis (calculated by Psoriasis Area and Severity Index (PASI) score); scale range of 0 to 72, 72 being maximal disease.",
                    "timeFrame": "Baseline, 3 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years of age or older\n* Patients with moderate-severe psoriasis or \\> 5% body surface area affected.\n\nExclusion Criteria:\n\n* taking systemic immunosuppressives in the last 4 weeks\n* pregnancy\n* severe immunodeficiency (either from genetic or infectious causes).\n* tuberculosis or other active serious infection\n* active systemic malignancy.\n* breast-feeding\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Raymond Cho, MD, PhD",
                    "role": "CONTACT",
                    "phone": "415-575-0524",
                    "email": "rashes@ucsf.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Raymond Cho, MD, PhD",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94115",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Raymond Cho, MD, PhD",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011565",
                    "term": "Psoriasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017444",
                    "term": "Skin Diseases, Papulosquamous"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14422",
                    "name": "Psoriasis",
                    "asFound": "Psoriasis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19713",
                    "name": "Skin Diseases, Papulosquamous",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000911",
                    "term": "Antibodies, Monoclonal"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "asFound": "Chlordiazepoxide",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}